Quick Facts

• Addresses: Nausea, vomiting, and feelings of discomfort related to the upper stomach.
• Supports: Symptom management for conditions associated with slow stomach movement (gastroparesis).
• Assists with: Relief of symptoms associated with indigestion, such as bloating and stomach fullness.

---

What Degut Treats: Main Uses and Benefits

Degut is a prescribed medication intended for the management of various symptoms related to upper gastrointestinal discomfort and motility concerns. The primary therapeutic focus involves providing relief from feelings of nausea and episodes of vomiting.

It is also indicated for the symptomatic support of dyspepsia, a term that includes sensations of fullness, bloating, and discomfort in the upper stomach area. This medication is utilized to ease these types of gastric discomforts, particularly when they may be linked to delayed gastric emptying (the slow movement of food from the stomach).

Furthermore, Degut may be administered to address and help mitigate nausea and vomiting that may arise as a secondary effect of certain treatments, such as those used for Parkinson's disease. Domperidone (the active compound associated with Degut) is utilized for specific, serious gastrointestinal conditions.

Official Eligibility Profile for Degut

Regulatory agencies define strict criteria for who can and cannot use Degut, focusing on absolute exclusions (contraindications) and populations requiring special caution or use limitations.

Classification	Official Restriction Summary
Contraindicated Populations	Patients with known hypersensitivity to the drug or its excipients. Individuals with pre-existing cardiac conditions causing QTc prolongation or those with moderate or severe hepatic impairment.
Prohibited Conditions	Use is forbidden in clinical conditions where gastrointestinal stimulation is harmful, such as mechanical obstruction, perforation, or hemorrhage. Concomitant use with specific strong drug inhibitors (e.g., potent CYP3A4 inhibitors) is also prohibited.
Pregnancy & Lactation	Use is generally contraindicated during pregnancy due to potential fetal risk. The drug is not recommended for nursing mothers as it is excreted into breast milk.
Age & Organ Function	Pediatric use is generally not established and often restricted. Older adults require mandatory caution and lower maximum doses due to increased cardiac risk. Patients with renal impairment require cautious use, with dose adjustments specified in labeling for severe impairment.

These constraints define the official eligibility profile by mandating the exclusion of high-risk groups and establishing conditional use for populations with impaired organ function or heightened susceptibility to adverse effects, as documented in governmental labeling.

Interactions with other medicines and products

The official interaction profile for Degut (Domperidone) is defined by mandatory constraints related to cardiovascular risk and metabolic inhibition. Co-administration is formally contraindicated with two major categories of medicinal products. The first is any medicine documented to prolong the QTc interval, which includes specific anti-arrhythmics, antipsychotics, and antidepressants. The second is any Potent CYP3A4 Inhibitor, such as systemic azole antifungals (e.g., ketoconazole) and certain macrolide antibiotics (e.g., clarithromycin). These inhibitors prevent the normal elimination of Domperidone, leading to elevated plasma concentrations and increased cardiac risk.

---

Interactions also dictate specific administration requirements. Domperidone's principal metabolic pathway involves the CYP3A4 enzyme, and it is a P-glycoprotein substrate. While potent inhibitors are prohibited, moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil) may increase exposure and require caution. Furthermore, co-administration with Antacids or Antisecretory Agents reduces the oral bioavailability of Degut, necessitating a separation of timing between administrations. Absorption is also delayed and reduced when Degut is taken with food. The medicine is formally contraindicated in patients with moderate or severe hepatic impairment due to the resulting significantly increased systemic exposure.

The action of Domperidone is based on its role as a selective dopamine receptor antagonist, primarily targeting the D2 and D3 receptors outside the central nervous system (CNS). This mechanism is defined by a dual physiological effect: increasing the contractility of the upper digestive tract and inhibiting the signal transmission within the emesis reflex pathway.

The molecule's primary molecular target for its anti-emetic mechanism is the Dopamine D2 receptor within the Chemoreceptor Trigger Zone (CTZ). This area lies outside the Blood-Brain Barrier (BBB), allowing the molecule to block chemical signals sampled by the CTZ; its low BBB penetration limits its interaction with deep CNS pathways. The physiological consequence of this blockade is the inhibition of the emesis reflex signal transmission.

The second domain involves the Enteric Nervous System (ENS). Dopamine naturally inhibits gut contractility by reducing acetylcholine ( ACh) release. By antagonizing the D2 receptors, Domperidone removes this inhibitory signal, leading to an increase in ACh release. This mechanistic cascade results in increased frequency and force of peristalsis and a change in the rate of gastric emptying.

This prokinetic mechanism depends on the downstream ACh signal to modulate gastrointestinal contractility. Therefore, concurrent use of medications that block ACh receptors, such as anticholinergics, can functionally negate Domperidone's effect, highlighting a key mechanistic limitation.

How to Use Degut

The administration of Degut (Domperidone) focuses on precise dosing, timing, and duration. The medicine is available for administration via the oral route (tablet, suspension) and the rectal route (suppository).

---

Official Dosing and Schedule

Usage Entity Map (High-Level)	Official Instruction/Regimen (Adults & Adolescents 12 years & 35 kg)
Standard Oral Dose	10 mg per dose, up to three times per day (TID)
Maximum Daily Oral Dose	30 mg/day
Rectal Dose	30 mg per dose, up to twice daily (BID)
Dosing Interval	Doses should be separated by approximately 8 hours

---

Administration Requirements

Specific requirements exist for proper use. To optimize systemic uptake, Degut is recommended to be taken 15 to 30 minutes before a meal. The treatment is restricted to the lowest effective dose for the shortest duration necessary, and generally should not exceed 7 days. If a scheduled dose is missed, it must be omitted, and the patient should resume the next dose at the regular time; a double dose must not be taken.

Population-Specific Use

Adjustments are required for certain populations. For patients with severe renal impairment, the dosing frequency must be reduced to once or twice daily. Furthermore, due to the need for accurate dosage, tablets and suppositories are generally unsuitable for use in adolescents weighing less than 35 kg.

Research evidence / Overview of studies for Degut (Domperidone)

---

Evidence for Nausea and Vomiting Symptoms

Domperidone was evaluated in short-term Randomized Controlled Trials (RCTs) and systematic reviews used in research exploring how symptoms change over time. These studies were relevant in trials assessing short-term or episodic symptom patterns for research exploring general symptoms of nausea and vomiting. Study populations included both adults and children facing acute episodes of sickness. Research highlights changes measured during the study period, but findings were mixed across studies, particularly when looking at results in children. Evidence is limited regarding outcomes beyond the initial short-term period of up to four weeks, and long-term effects are not fully established through randomized, controlled evidence.

---

Evidence for Stomach Motility and Gastroparesis Symptoms

For conditions marked by functional limitations such as gastroparesis, studies utilized a mix of small RCTs and long-term observational data derived from patient registries. Research was applied in studies examining patient-reported experiences using tools like the Gastroparesis Cardinal Symptom Index (GCSI) and objective measurements of gastric emptying time. Data show patterns related to tracking of symptom management, especially in the observational settings. Data for certain groups remain insufficient, and the observational study designs used for long-term outcomes mean that establishing cause-and-effect patterns is limited. Evidence is particularly focused on those who had previously not responded to other treatments.

---

Evidence in Special Populations and Research Gaps

Research examined Domperidone use in special populations, including studies that evaluated children (pediatric patients) and adults with specific comorbid conditions, such as diabetic gastroparesis. Findings related to outcomes were observed in these specific patient groups. However, data for certain groups remain insufficient, including pregnant populations and older adults with significant comorbidities, where research is limited. The evidence base describes limitations, including the lack of comparative evidence against newer therapeutic options and the fact that long-term effects are not fully established through high-certainty research for most indications.

Key Studies & References

1. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis (Cochrane/AHRQ Review)

Common questions about Degut (FAQ)

Q: What should I do if I think I've taken too much Degut (overdose)?

In cases of suspected overdose, immediate contact with a poison control center or emergency services is typically recommended. Regulatory documents describe symptoms observed following an overdose, which may include agitation, altered consciousness, or involuntary muscle movements. The management of an overdose usually involves supportive care and symptomatic treatment.

---

Q: What food or drinks should I avoid while taking Degut?

Official information indicates that the absorption of Degut is reduced when taken with food. To help optimize the absorption of the medicine, official information suggests taking it before a meal. Some regulatory documents also discourage the use of grapefruit juice because it may interfere with the medicine's metabolic process.

---

Q: What should I do if I start getting involuntary muscle movements (oculogyric crisis or convulsions)?

Regulatory documents describe that the occurrence of serious effects like convulsions or extrapyramidal disorders (such as involuntary eye or muscle movements) is considered rare. Official labeling states that if these severe effects are experienced, the medicine should be discontinued immediately, and urgent medical assistance should be sought.

---

Q: How long is Degut safe to use for my symptoms?

Regulatory guidance specifies that treatment duration should be limited to the shortest time necessary to relieve symptoms. The official label indicates that the duration of use generally should not exceed 7 consecutive days.

---

Q: What should I do if I forget to take a dose of Degut?

Official instruction states that a missed scheduled dose should be omitted. The patient should then take their next dose at the regular scheduled time. Furthermore, regulatory information specifies that a double dose must not be taken to make up for the missed one.

---

Q: Can I crush or split the Degut tablets before taking them?

Official product information does not specifically authorize crushing or splitting the tablets. However, if a patient is unable to swallow solid medicine, Degut is manufactured in alternative dosage forms, such as an oral suspension or an oral lyophilisate (a tablet that dissolves in the mouth).

---

Q: What are the most common side effects of Degut?

Based on clinical studies and official regulatory labeling, the most frequently reported adverse reaction is dry mouth. The full safety information section lists other adverse reactions that occur less commonly.

---

Q: What is the recommended storage temperature for Degut?

Official storage instructions require that Degut be kept at a temperature below 30 C. The medicine must also be protected from light and moisture to ensure its stability.

---

Q: How should I properly dispose of expired Degut medication?

To ensure environmental protection, official instructions specify that disposal is typically achieved by returning the product to a pharmacist or utilizing a recognized local medicine take-back program. The medicine must not be disposed of by flushing it into wastewater systems.

---

Q: When is the best time to take Degut: before or after a meal?

Official information indicates that taking the medicine 15 to 30 minutes before a meal is suggested to help optimize its absorption. Taking Degut with food is known to reduce the amount of medicine absorbed by the body.

How to Store and Dispose of Degut: Official Regulatory Information

Official labeling for Degut establishes mandatory requirements for its storage and disposal to ensure stability and safety.

---

Storage Requirements

The product must be stored below 30 C and is required to be protected from light and moisture. To maintain its stability, the medication must be kept in its original packaging until the labeled expiry date. A key child-safety measure is the regulatory instruction to keep Degut out of children's reach.

Disposal Instructions

Expired or unused Degut should be disposed of by utilizing official medicine take-back programs available nationally or locally. Government guidance specifies that the product must not be disposed of by flushing or introduction into wastewater systems, thereby ensuring environmental protection.